期刊文献+

DE与DX新辅助化疗治疗乳腺癌后的影像学检查及近期疗效观察

下载PDF
导出
摘要 目的:比较DE与DX两种不同新辅助化疗方案治疗乳腺癌的近期疗效、副反应及影像学检查。方法:采用多西他赛联合表柔比星DE(23例)或多西他赛联合卡培他滨DX(22例)方案新辅助化疗4周期的乳腺癌患者45例进行回顾性分析,应用影像学检查分别比较两组方案的近期疗效及其不良反应。结果:两组的RR和p CR率均无统计学差异(P>0.05)。DE组的毒副反应较明显,Ⅲ/Ⅳ级粒细胞减少,不同程度的恶心呕吐,差异有统计学意义(P<0.05)。结论:DE和DX两组新辅助化疗方案对乳腺癌均有一定疗效。DX组不良反应较DE组轻,具有更高安全性。
作者 张淼
出处 《中国医疗器械信息》 2017年第16期139-140,共2页 China Medical Device Information
  • 相关文献

参考文献1

二级参考文献25

  • 1Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-nega- tive breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer, 2011, 18 (3) : 165-173.
  • 2Bernsdorf M, Ingvar C, Jorgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat, 2011, 126(2) : 463-470.
  • 3Iwata H, Sato N, Masuda N, et al. Docetaxel followed by fluoroura- cil/epirubiein/cyclophosphamide as ,neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol, 2011,41 (7) : 867-875.
  • 4Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the ef- fectiveness of neoadjuvant chemotherapy and prognosis in triple-nega- tive breast cancer patients. Cancer Chemother Pharmacol, 2011, 67 (4), 911-917.
  • 5Stefansson OA, Jonasson JG, Olafsdottir K, et al. CpG island hyper- methylation of BRCA1 and loss of pRb as co-occurring events in bas- al/triple-negative breast cancer. Epigenetics, 2011,6 (5) : 638-649.
  • 6Pierga JY, Delaloge S, Espie M, et al. A muhicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat, 2010, 122(2) : 429-437.
  • 7Juul N, Szallasi Z, Eklund AC, et al. Assessment of an RNA inter- ference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-nega- tive breast cancer: a retrospective analysis of five clinical trials. Lan- cet Oncol, 2010, 11 (4) : 358-365.
  • 8Sirohi B, Amedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol, 2008, 19 ( 11 ) : 1847- 1852.
  • 9Kennedy CR, Gao F, Margenthaler JA. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer. J Surg Res, 2010, 163(1) : 52-57.
  • 10Kaplan HG, Malmgren JA, Atwood M. T1 NO triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J, 2009, 15(5) : 454-460.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部